Galantamine has been shown to improve memory and behavioral symptoms in patients with Alzheimer's disease and may have disease modifying properties. All subjects who complete the study or show significant memory decline during the course of the study will receive open label galantamine. Subjects must be willing to have 4 MRI scans over the course of the study and must be willing to bring a reliable informant to all study visits.
Parking is reimbursed.
If you would like to learn more about participating in this study, please send an e-mail message using the form below. Please be assured that your message has been received. This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.